XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash $ 2,120,243 $ 6,611,928
Accounts receivable, net of allowance for bad debt of $65,719 and $60,012 1,792,334 1,285,165
Royalty receivable 49,344 50,250
Inventory, net of allowance for obsolescence of $231,342 and $43,650 787,822 746,519
Prepaid other - related party 50,970 0
Prepaid and other assets 482,097 161,902
Total current assets 5,282,810 8,855,764
Long-term assets    
Property, plant and equipment, net of accumulated depreciation of $107,443 and $60,694 208,919 204,953
Right of use assets - operating leases 497,748 585,251
Intangible assets, net of accumulated amortization of $762,594 and $603,580 3,162,181 1,471,194
Investment in equity securities 500,000 0
Total long-term assets 4,368,848 2,261,398
Total assets 9,651,658 11,117,162
Current liabilities    
Accounts payable 274,570 337,504
Accounts payable - related party 94,807 68,668
Accrued royalties and expenses 668,958 528,060
Accrued bonus and commissions 1,813,153 1,588,056
Operating lease liability - current 124,263 117,533
Short-term debt 114,975 0
Accrued interest 2,559 0
Total current liabilities 3,093,285 2,639,821
Long-term liabilities    
Operating lease liability - long term 387,567 481,384
Convertible notes payable - related party 0 1,500,000
Long-term debt 468,025 0
Accrued interest - related party 0 103,557
Other long-term liabilities 139,437 0
Total long-term liabilities 995,029 2,084,941
Total liabilities 4,088,314 4,724,762
Shareholders' equity    
Series F Convertible Preferred Stock: $10 par value, 1,200,000 shares authorized; none issued and outstanding as of September 30, 2020 and 1,136,815 issued and outstanding as of December 31, 2019 0 11,368,150
Common Stock: $0.001 par value, 20,000,000 shares authorized; 6,279,610 issued and outstanding as of September 30, 2020 and 3,571,001 issued and outstanding as of December 31, 2019 6,280 3,571
Additional paid-in capital 12,633,248 (2,081,829)
Accumulated deficit (6,785,749) (2,675,802)
Total Sanara MedTech shareholders' equity 5,853,779 6,614,090
Equity attributable to noncontrolling interest (290,435) (221,690)
Total shareholders' equity 5,563,344 6,392,400
Total liabilities and shareholders' equity $ 9,651,658 $ 11,117,162